Conference Coverage
Conference Coverage
Psoriasis duration reflects cardiovascular event risk
For every year of psoriasis, a patient’s risk of a major cardiovascular event climbs an additional 1%.
Conference Coverage
Is PASI 100 the new benchmark in psoriasis?
KAUAI, HAWAII – “I think we should just do away with PASI 90 and look at how well our drugs do against the metric of PASI 100.”
Conference Coverage
How to avoid severe diarrhea from apremilast
Delayed up-titration of apremilast is often effective, albeit at cost of slower efficacy.
Conference Coverage
PASI responses with biologics similar among white, nonwhite individuals, study finds
MIAMI– Investigators used data from psoriasis studies to determine whether treatment responses differed in skin of color patients.
Conference Coverage
Study highlights need to investigate psoriasis treatment outcomes in skin of color patients
MIAMI – Researchers used phase 2 and 3 psoriasis clinical trial data to explore potential differences in treatment response in various ethnic...
Conference Coverage
2017 was a big year for psoriatic arthritis
MAUI, HAWAII – “There is a tremendous amount of excitement now in the field of psoriatic arthritis.” – Arthur Kavanaugh, MD.
Conference Coverage
Psoriatic arthritis treatment: “We’re not doing so well”
MAUI, HAWAII – “Psoriatic arthritis lags behind rheumatoid arthritis, maybe by a decade,” despite current treatments and a treat-to-target...
Conference Coverage
VIDEO: PPACMAN aims to advance the combined rheum-derm clinic approach in the community
SAN DIEGO - The idea behind starting PPACMAN the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Networkwas to form clinics at...
Conference Coverage
Could guselkumab be a disease-modifying agent in plaque psoriasis?
SAN DIEGO – Questions remain about why some patients maintain durable response.
Conference Coverage
Ustekinumab quells aortic inflammation in patients with severe psoriasis
SAN DIEGO – The benefit may be a class-associated effect.